Major Shareholder & Director Group Invests $5M in Recent Offering

summarizeSummary

venBio Global Strategic Fund, a major shareholder group including directors Corey Goodman and Robert Adelman, purchased $5 million worth of ALX Oncology stock in the company's recent follow-on offering, demonstrating significant confidence.

check_boxKey Events

• Significant Insider Investment

  venBio Global Strategic Fund, a major shareholder group including directors Corey Goodman and Robert Adelman, purchased approximately $5 million in ALX Oncology common stock.

• Participation in Follow-on Offering

  The purchase of 3,184,713 shares at $1.57 per share was part of the company's $150 million public offering that closed on February 2, 2026. The stock is currently trading at $2.19, near its 52-week high of $2.27.

• Updated Beneficial Ownership

  Following the transaction, Corey Goodman's beneficial ownership stands at 10%, and Robert Adelman's at 9.9%, reflecting their continued significant stake in the company.

auto_awesomeAnalysis

This Schedule 13D/A filing details the participation of venBio Global Strategic Fund, a significant institutional investor and a group that includes company directors Corey Goodman and Robert Adelman, in ALX Oncology's recent $150 million public offering. The group invested approximately $5 million by purchasing 3,184,713 shares at the offering price of $1.57 per share. This substantial investment, representing a significant portion of the company's market capitalization, signals strong conviction from a key insider and institutional shareholder group following a dilutive capital raise. This follows the company's announcement of positive clinical data and the pricing of the offering on January 30, 2026, and a related Form 4 filing on February 4, 2026, which reported a similar purchase by a director and 10% owner.